

1 **Title:** Treatment of Early Hypertension among Persons Living with HIV in Haiti: protocol for a
2 randomized controlled trial

3 **Authors:**

4 Lily D Yan^{*1,2,3}, Vanessa Rouzier^{*2,3}, Eliezer Dade³, Collette Guiteau³, Jean Lookens Pierre³, Stephano St-
5 Preux³, Miranda Metz², Suzanne Oparil⁴, Jean William Pape^{2,3}, Margaret McNairy^{1,2,3}

6

7 **Affiliations:**

8 1. Division of General Internal Medicine, Department of Medicine, Weill Cornell Medicine, New York,
9 New York, USA

10 2. Center for Global Health, Department of Medicine, Weill Cornell Medicine, New York, New York, USA

11 3. Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Port-au-
12 Prince, Haiti

13 4. Division of Cardiovascular Disease, Department of Medicine, University of Alabama at Birmingham,
14 Birmingham, Alabama, USA

15 *co-first authors

16 corresponding author: Lily D. Yan, liy9032@med.cornell.edu

17

18

19

20

21

22

23 **Abstract**

24 Background

25 People living with HIV (PLWH) are at increased risk of cardiovascular disease (CVD) and death, with
26 greater burdens of both HIV and CVD in lower-middle income countries. Treating prehypertension in
27 PLWH may reduce progression to hypertension, CVD risk and potentially mortality. However, no trial has
28 evaluated earlier blood pressure treatment for PLWH. We propose a randomized controlled trial to
29 assess the feasibility, benefits, and risks of initiating antihypertensive treatment among PLWH with
30 prehypertension, comparing prehypertension treatment to standard of care following current WHO
31 guidelines.

32 Methods

33 A total of 250 adults 18-65 years and living with HIV (PLWH) with viral suppression in the past 12
34 months, who have prehypertension will be randomized to prehypertension treatment versus standard
35 of care. Prehypertension is defined as having a systolic blood pressure (SBP) 120-139 mmHg or diastolic
36 blood pressure (DBP) 80-89 mmHg. In the prehypertension treatment arm, participants will initiate
37 amlodipine 5 mg daily immediately. In the standard of care arm, participants will initiate amlodipine
38 only if they develop hypertension defined as SBP \geq 140 mmHg or DBP \geq 90 mmHg. The primary outcome
39 is the difference in mean change of SBP from enrollment to 12 months. Secondary outcomes include
40 feasibility, acceptability, adverse effects, HIV viral suppression, and medication adherence. Qualitative
41 in-depth interviews with providers and participants will explore attitudes about initiating amlodipine,
42 satisfaction, perceived CVD risk, and implementation challenges.

43 Discussion

44 PLWH have a higher CVD risk and may benefit from a lower BP threshold for initiation of
45 antihypertensive treatment.

46 Trial registration

47 Clinicaltrials.gov registration number NCT04692467, registration date December 15, 2020, protocol ID
48 20-03021735.

49

50 **Keywords**

51 Prehypertension; HIV/AIDS; low-middle income country; Haiti; clinical trial; amlodipine

52

53

54

55

56

57

58

59

60

61

62

63 **Background**

64 People living with HIV (PLWH) are at an increased risk of cardiovascular disease (CVD), including
65 hypertension, myocardial infarction (MI) and stroke due to a complex interplay between increased
66 inflammation from HIV, adverse effects of antiretroviral therapy (ART), and traditional host risk factors
67 (1). Hypertension prevalence is 35% for PLWH on ART, and the relative risk for MI and stroke is as much
68 as two-fold higher in PLWH compared to people without HIV (2–6).

69 The highest burden of HIV has long been in low- and middle-income countries (LMICs) (7). The majority
70 of persons with hypertension are now also located in LMICs—an estimated 1.04 billion—compared to
71 349 million in high-income countries (HIC) (8). High systolic blood pressure (SBP) has become the leading
72 risk factor for all-cause mortality in the world over the past 30 years (9). Haiti exemplifies this dual
73 burden, with the highest HIV prevalence in the western hemisphere (10), and an age-standardized
74 hypertension prevalence of 29% (11,12). Our prior research has shown that among PLWH in Haiti,
75 hypertension is independently associated with increased mortality (HR 2.47 [95% CI 1.10-5.57]), after
76 adjusting for immune status, age, and sex (13).

77 Given the step-wise increased risk of CVD events and mortality among people with elevated SBP > 115
78 mmHg (14,15), there may be significant benefits to treating prehypertension, defined as SBP 120-139
79 mmHg or diastolic blood pressure (DBP) 80-89 mmHg. Treatment of prehypertension not only prevents
80 progression to hypertension (16), it can also decrease CVD events and disease progression in people
81 with diabetes, chronic kidney disease (CKD), and nonobstructive coronary artery disease (17–20).

82 Haiti guidelines for hypertension treatment follow the World Health Organization (WHO) guidelines,
83 which recommend initiating antihypertensive treatment at SBP \geq 140 mmHg or DBP \geq 90 mmHg for the
84 general adult population, and at SBP \geq 130 mmHg or DBP \geq 80 mmHg for high risk groups such as people
85 with diabetes or CKD (21). In contrast, the 2017 American College of Cardiology / American Heart

86 Association (ACC/AHA) guidelines recommend treatment initiation at SBP ≥ 140 mmHg or DBP ≥ 90
87 mmHg for people with 10 year predicted CVD risk $< 10\%$, and at SBP ≥ 130 mmHg or DBP ≥ 80 mmHg for
88 people with 10 year predicted CVD risk of $\geq 10\%$ (22). The WHO does not include PLWH in their
89 definition of high-risk groups despite PLWH having a similarly increased CVD risk compared to people
90 with diabetes or CKD (1). The AHA/ACC guidelines also do not adequately capture risk in PLWH given
91 traditional 10 year CVD risk prediction models underestimate risk for PLWH (23).

92 The Treatment of Early Hypertension among Persons Living with HIV randomized controlled trial aims to
93 assess the feasibility, benefits, and risks of initiating antihypertensive treatment among PLWH with
94 prehypertension, comparing prehypertension treatment to the WHO standard of care in parallel groups.
95 These data will inform a future large trial, designed with sufficient power to detect clinically significant
96 differences in BP, and differences in rates of CVD events and mortality, between a prehypertension
97 treatment versus standard of care arm among PLWH.

98 **Methods**

99 Study design and site

100 This is an unblinded randomized controlled trial of 250 PLWH, with half randomized to the
101 prehypertension treatment arm, and half to the standard of care. All participants have prehypertension,
102 defined as SBP 120-139 mmHg or DBP 80-89 mmHg at two separate clinic visits. In the prehypertension
103 treatment arm, participants will be started on amlodipine 5mg daily at enrollment. In the standard of
104 care arm, participants will not be started on amlodipine at enrollment.

105 The study site is the Groupe Haitien d'Etude du Sarcome de Kaposi et des Infections Opportunistes
106 clinics (GHESKIO) in Port-au-Prince, Haiti. GHESKIO is a medical facility that has operated continuously
107 over the past 40 years conducting clinical care, research, and advocacy for PLWH and associated chronic

108 diseases with over 600,000 patient visits annually. This study will recruit patients from the GHESKIO's
 109 Adult HIV Clinic, which cares for over 175,000 patients annually with HIV.

110 Study population

111 The study population will include 250 PLWH receiving HIV care at GHESKIO. People aged 18-65 years of
 112 age on ART for one year, with HIV viral load suppression defined as < 1000 copies/ml in the past 12
 113 months, and with confirmed prehypertension (SBP 120-139 mmHg or DBP 80-89 mmHg) not currently
 114 on antihypertensives will be included (Table 1). Younger PLWH are intentionally included as
 115 hypertension prevalence among young adults in Haiti is up to three-fold higher (10,11) than among age-
 116 matched African Americans in US cohorts (24). Participants with CKD or diabetes are excluded as Haitian
 117 guidelines initiate treatment at a threshold of SBP \geq 130 mmHg or DBP \geq 80 mmHg. PLWH on a protease
 118 inhibitor such as ritonavir are excluded because of possible drug-drug interactions with amlodipine (25).

119 **Table 1: Inclusion and exclusion criteria for study population**

Inclusion criteria	Exclusion criteria
PLWH 18-65 years of age	Pregnancy
ART duration \geq 1 year, stable regimen \geq 6 months	Chronic kidney disease or diabetes
Viral suppression: HIV 1-RNA < 1,000 copies/mL within past 12 months	On protease inhibitor
Prehypertension: SBP 120-139 and DBP < 90, OR SBP < 140 and DBP 80-89 mmHg	Advanced illness with limited life expectancy
Not currently on antihypertensive medications	Plans to move out of the area within the next year
Receives HIV care at GHESKIO	Clinician determination that patient is unstable on ART
Willing to provide consent	

120

121 Intervention

122 The study intervention in the prehypertension treatment arm is initiation of amlodipine 5mg daily
 123 immediately. The study intervention in the standard of care arm is initiation of amlodipine 5mg daily

124 only if participants develop incident hypertension (SBP \geq 140 mmHg or DBP \geq 90 mmHg) during the
125 course of the study, as recommended by Haiti's hypertension treatment guidelines (21,26). Throughout
126 the follow-up period, if a participant randomized to the prehypertension treatment arm has a SBP \geq 130
127 mmHg after 1 month of treatment, amlodipine will be increased from 5mg to 10mg. If a participant
128 develops new or changing symptoms, he/she will be referred to GHESKIO's CVD clinic for medical care
129 by clinic staff.

130 Amlodipine discontinuation or dose decrease will be based on development of adverse effects or
131 participant request, after review by an independent Drug and Safety Monitoring Board composed of
132 external experts in cardiovascular clinical research and biostatistics. Adverse events include dizziness,
133 fainting, and lower extremity edema. Only Grade III-V adverse effects will trigger amlodipine
134 discontinuation, modeled after the NIH Division of AIDS (DAIDS) Table for Grading Severity of Adult and
135 Pediatric Adverse Events (27).

136 Study visits and measurements

137 There are four categories of study visits: recruitment and screening, enrollment, follow-up, and a final
138 12-month visit (Figure 1).

139 **Figure 1: Study Overview**

140

141 Legend: Study follow-up visits will occur in the GHESKIO Clinic, with community visits to measure BP
142 offered in months 2, 5, and 8.

143 *Recruitment, screening and informed consent*

144 Participant recruitment will occur at the GHESKIO Adult HIV clinic as well as through a review of the
145 GHESKIO electronic medical record to pre-identify PLWH who meet inclusion criteria. Individuals will
146 then be invited for a screening visit and informed consent.

147 In the first part of the screening visit, study eligibility criteria will be evaluated and blood pressure (BP)
148 will be measured. Two BP measurements, on different days, in the prehypertensive range are needed to
149 qualify for the study.

150 All BP measurements will follow ACC/AHA and WHO international guidelines (21,22). We will use semi-
151 automated electronic cuffs (OMRON 742-5 series in the community, OMRON HEM 907 in clinic). After
152 resting for 5 minutes, the participant will have three BPs measured, separated by 1-minute intervals.
153 The average of the 3 BPs is the BP for the study visit.

154 Individuals found to have at least two BPs in the prehypertensive range will be introduced to the study
155 by research staff, and if interested in participating, will provide written informed consent. Subsequent
156 screening procedures for consented participants include screening labs for pregnancy, diabetes, and
157 CKD (Table 2). Those without evidence of pregnancy, diabetes and or renal disease will proceed with
158 randomization.

159 *Enrollment procedures*

160 The study enrollment visit includes a questionnaire, physical exam, and laboratory tests. The
161 questionnaire includes demographic and socioeconomic information and information about
162 cardiovascular disease health behaviors using validated instruments on smoking (36), diet (36), alcohol
163 use (37), and physical activity (38). Medical history of cardiovascular risk factors, HIV, tuberculosis, and
164 family history of cardiovascular disease will be ascertained. Vital signs, including BP, will be obtained and
165 a physical exam will be performed. Laboratory data including total cholesterol, high density lipoprotein

166 (HDL), CD4 cell count, and HIV-1 RNA viral load will be collected. Lastly, an EKG and echocardiogram will
167 be performed.

168 Patients will be randomized to the 1) prehypertension treatment arm, or 2) standard of care arm in
169 blocks of 10 using a random number generator by the GHESKIO Clinical Trial Unit's computer algorithm.

170 *Follow-up study visits*

171 Participants will be evaluated at five study visits during the 12-month follow-up at GHESKIO (Figure 1).

172 The first will occur within 1 month of enrollment to evaluate response to initiation of amlodipine (if
173 applicable). Subsequent visits will occur in months 3, 6, 9 and 12. Each will include BP measurement,
174 evaluation for medication adherence, drug side effects, and inquiry about interim hospitalizations.

175 Research staff will review outside hospitalizations for new CVD-related diagnoses and events. Every visit
176 will include lifestyle counseling on diet, exercise, and general medication adherence. ART adherence will
177 be measured using validated AACTG Adherence Instruments (28), and amlodipine adherence will be
178 measured using the Hill-Bone instrument (29). At the 12-month visit, a physical exam, study
179 questionnaire about health behaviors, and a HIV-1 RNA viral load assessment will be performed. ART will
180 be distributed in 6-month supply per national guidelines in both study arms. Amlodipine will be
181 distributed in 3-month supply after the first follow-up visit.

182 In addition, follow-up visits at months 2, 5, and 8 will take place in the community at the location of
183 participant preference. These visits will include the same assessments.

184 *In-depth interviews*

185 In-depth interviews will be conducted by study healthcare providers (physicians, nurses) in a subset of
186 30 participants in the prehypertension treatment arm. We will explore attitudes about initiating
187 amlodipine in addition to existing HIV medications, positive and negative perceptions about amlodipine,

188 satisfaction with treatment, intent to continue treatment, home BP measurement, and perceived CVD
189 risk. We will interview providers about implementation challenges and unintended consequences.
190 Interviews will be conducted in Creole, audio-recorded, transcribed verbatim, and translated into
191 English for analysis using Atlas-ti.

192 All study data will be collected on a secure web platform using REDCap (supported by the National
193 Center for Advancing Translation Science of the National Institute of Health under award number
194 UL1TR002384).

195 **Table 2: Study Measures and Schedule**

TIMEPOINT	SCREENING VISIT	ENROLLMENT	M1	M2*	M3	M5*	M6	M8*	M9	M12
SCREENING										
Screening Labs: urine/serum pregnancy test, fasting or random glucose, creatinine	X									
ENROLLMENT										
Demographics: age, sex		X								
Socioeconomic factors: income, education, occupation, marital status, children.		X								
Medical History: history of CVD risk factors and diseases HIV, tuberculosis		X								
Family History: stroke, myocardial infarction, or heart failure in parents and 4 oldest siblings		X								
Health behaviors: current cigarette smoking, alcohol, physical activity		X								X
Multidimensional Poverty: child death, educational attainment, household construction materials, possessions		X								
Allocation		X								
INTERVENTIONS										
Treatment of Prehypertension		X	X	X	X	X	X	X	X	X
Standard of Care		X	X	X	X	X	X	X	X	X
ASSESSMENTS										
Physiologic: height, weight		X								X
Blood pressure		X	X	X	X	X	X	X	X	X
ECG		X								
Echocardiography and vascular ultrasound		X								
Enrollment Labs: total cholesterol, HDL, CD4, HIV-1 RNA viral load		X								
12M Labs: HIV-1 RNA viral load										X
Medical record abstraction: diagnoses codes (ICD-9), laboratory measures, diagnostic imaging, and cause of death among participants who receive clinical care from the GHESKIO NCD clinic, a GHESKIO-affiliated hospital, or other health facility			X	X	X	X	X	X	X	X
Adverse Events: if in treatment group			X	X	X	X	X	X	X	X
In depth Interviews										X
Medication Adherence (ART and amlodipine)		X	X	X	X	X	X	X	X	X

196

197 Legend: * indicates a study visit in the community.

198 Study outcomes and measures

199 The primary outcome is the change in mean SBP (mmHg) from enrollment to 12 months and the
200 difference in this change between the two study arms. Secondary outcomes include feasibility,
201 acceptability, adverse effects, HIV viral suppression at 12 months, and ART medication adherence.
202 Feasibility will be measured as the percent of participants retained between enrollment and 12 months,
203 across both study arms and adherence to amlodipine using a validated scale (29). Acceptability will be
204 measured through key themes that emerge from semi-structured key informant qualitative interviews
205 with participants and providers (e.g. perceived benefits of amlodipine, perceived harms). Adverse
206 effects will be measured as number of subjects who have adverse events related to amlodipine,
207 including dizziness, fainting, lower extremity edema, and any other symptoms which may be related.
208 Changes in HIV viral suppression will be measured as the change in number of participants with HIV-1
209 RNA viral loads < 1,000 copies/mL from enrollment to 12 months. HIV medication adherence will be
210 measured by number of participants with > 90% adherence using 4 day pill recalls (28).

211 Power and sample size calculations

212 With a sample of 250 participants across both arms and 8 time points for BP measurements for each
213 participant, we have 80% power with alpha 0.05 to detect a difference in change in SBP of 4 mmHg or
214 more between the study arms at 12 months (assuming consistent difference across time and a
215 conservative correlation among measurement of 0.95, standard deviation of BP at each time point = 25
216 mmHg) (30). We will present summary statistics (e.g., mean and SD of pre, post, and difference within
217 and between arms).

218 Statistical methods

219 For the primary outcome, we will compare the mean difference in change in SBP among participants
220 from enrollment to 12 months in each study arm using linear mixed-effects model (LMM) accounting for

221 repeated measures and correlations within subjects, where the time*treatment interaction will serve as
222 the “primary” parameter addressing differential slopes for the two arms. We anticipate that the two
223 arms will have similar baseline characteristics due to randomization, and therefore the primary analysis
224 will not adjust for baseline variables. If baseline variables are imbalanced, we will adjust factors in
225 regression and report the findings as a sensitivity analysis. We will assess the incidence of HTN using
226 Kaplan Meier methods. We will analyze dichotomized outcomes (SBP <120 and DBP <80) at all time
227 points via a generalized mixed-effects model and at 12 months via Fisher exact tests and logistic
228 regression.

229 In other sensitivity analyses, we will explore the following issues: 1) compliance/adherence (per protocol
230 analysis); 2) missing data/dropout (via last-value-carried-forward, multiple imputation or inverse-
231 probability weighting); 3) competing risks (e.g., death); 4) joint modeling (longitudinal and survival data);
232 and 5) changepoint (treatment initiation in standard of care arm).

233 For secondary outcomes, we will use a range of analytic methods. Feasibility will be measured as the
234 proportion of eligible participants willing to participate in the trial and their retention and the
235 proportion initiating amlodipine. The proportion of participants in each study arm with viral suppression
236 (HIV-1 RNA < 1000 copies/mL) at 12 months will be compared between study arms using the Fisher
237 exact test. We assume that participants who are lost to follow-up or dead at 12 months will have HIV-1
238 RNA > 1000 copies/mL. Other categorical data including medication adherence, CVD risk factors (e.g.
239 diabetes) will be analyzed similarly.

240 Longitudinal data such as adherence and adverse events (continuous or binary/categorical) will be
241 analyzed accounting for repeated measures within participants, via LMM and generalized LMM as
242 described above. We will also consider the generalized estimating equation-based method (so called,
243 marginal or population-averaged model) and will report consistency or meaningful discrepancy.

244 Acceptability will be assessed in qualitative interviews by trained research staff using interview
245 information transcribed verbatim, translated into English, and then coded for analysis using grounded
246 theory.

247 Ethics and dissemination

248 This study was approved by institutional review boards (IRBs) at Weill Cornell Medicine and GHESKIO.
249 Written informed consent by participants will be obtained by trained study personnel using existing
250 protocols in the GHESKIO Clinical Trial Unit, including testing for comprehension on study intervention
251 and measurements.

252 Important protocol modifications will be shared with investigators and trial participants within two
253 weeks, and submitted to IRBs and the trial registry within 30 days. Trial results will be communicated to
254 participants and local healthcare providers through a series of web-based and in-person presentations.
255 Results will be communicated to the public via publications and the clinicaltrials.gov registry.

256 **Discussion**

257 The purpose of the Treatment of Early Hypertension among Persons Living with HIV randomized
258 controlled trial is to assess the feasibility, benefits, and risks of initiating antihypertensive treatment
259 among PLWH with prehypertension. Treating prehypertension may reduce progression to hypertension
260 and reduce CVD risk and potentially CVD death in PLWH, and no trial has evaluated use of a lower BP
261 treatment threshold of SBP \geq 130 or DBP \geq 80 for this specific population. This trial is a first step towards
262 a large randomized controlled trial adequately powered for clinical outcomes, including CVD, to evaluate
263 the effects of prehypertension treatment in PLWH.

264 Prior research clearly links both hypertension and prehypertension to higher CVD risk and death in
265 PLWH. In the Veterans Aging Cohort Study Virtual Cohort, having HIV and prehypertensive BP was

266 associated with an increased risk of acute myocardial infarction compared to veterans without HIV, with
267 low prehypertensive BPs (SBP 120-129, DBP 80-84) HR 1.60 [95% CI 1.07-2.39] and high prehypertensive
268 BPs (SBP 130-139, DBP 85-89) HR 1.81 [95% CI, 1.22-2.68] (3). In Haiti, our prior research has shown that
269 hypertension in PLWH at the time of ART initiation is associated with increased mortality. In a cohort of
270 816 PLWH who started ART in 2005-2008 at GHESKIO, 5.3% had hypertension at the time of ART
271 initiation, and this independently predicted mortality during 10 years of follow-up (HR 2.47 [95% CI 1.10-
272 5.57]), after adjusting for age, sex, CD4 count at ART start (13). One third of the deaths were from
273 stroke.

274 This trial is designed to help fill in knowledge gaps including: Is it feasible to initiate and integrate
275 antihypertensive treatment into HIV care among a relatively healthy cohort of PLWH with
276 prehypertension? Could initiating first-line antihypertensive medication worsen HIV outcomes? What is
277 the BP reduction using amlodipine in PLWH? Data from this trial will inform the design of a larger
278 randomized trial powered for incident CVD events.

279 Our long-term goal is to change guidelines to institute earlier initiation of antihypertensive medication in
280 PLWH with prehypertension in order to prevent CVD in this population. The 2017 ACC/AHA guidelines
281 recommend using a combination of absolute CVD risk and BP level to guide treatment. However,
282 traditional 10 year CVD risk prediction models underestimate risk for PLWH, with poor to moderate
283 discrimination (c statistics 0.65 to 0.73), and higher observed versus predicted risk at all risk levels (31).
284 These guidelines may also be unduly burdensome to implement in low-middle income countries, where
285 laboratory tests for cholesterol may not be widely available or affordable. The SPRINT trial evaluated
286 initiating antihypertensive treatment to a goal of SBP \leq 120 mmHg among people with increased
287 cardiovascular risk, and found that intensive treatment resulted in fewer fatal and non-fatal CVD events
288 and all-cause mortality (20). Accurately capturing the increased CVD risk among PLWH and translating it

289 into an actionable treatment threshold is important, and one way to achieve this may be to enforce a
290 lower SBP treatment target.

291 Strengths of this study include a randomized controlled trial design to equally distribute covariates and
292 avoid omitted variable bias. Amlodipine is a relatively safe blood pressure medication, and requires no
293 lab testing for monitoring (unlike hydrochlorothiazide which requires checking blood electrolytes and
294 renal function). Frequent follow-up visits will closely monitor for hypotension and other adverse effects
295 of amlodipine, as well as track a possible impact on ART adherence. We include community-based BP
296 measurement which will allow assessment of BP in non-clinic settings. The study builds upon the strong
297 infrastructure of the HIV Clinic at GHESKIO, expanding its focus on CVD among PLWH. This will be among
298 the first studies evaluating BP in PLWH treated with dolutegravir, an ART associated with weight gain
299 that became the first-line regimen in Haiti and many other LMICs since 2018. Finally, we include
300 echocardiographic assessment of pre-existing myocardial and vascular dysfunction among PLWH, an
301 entity that has not been well described in the past. Our sample size of 250 participants is not powered
302 for CVD events.

303 **Conclusion**

304 There is an urgent need for CVD prevention among PLWH with elevated BP who have an alarmingly high
305 risk of CVD events and mortality. This study is the first step toward evaluating the feasibility, benefit,
306 and safety of earlier hypertension treatment of PLWH. Our data will inform a larger trial powered for
307 CVD events that could change the paradigm for hypertension treatment among PLWH.

308

309

310

311 **Declarations**

312 Ethics approval and consent to participate

313 This study was approved by institutional review boards at Weill Cornell Medicine and GHESKIO.

314 Consent for publication

315 Not applicable

316 Availability of data and materials

317 The datasets to be collected during the current study will be available from the corresponding author on
318 reasonable request. Data request should be submitted to Dr. Margaret McNairy
319 (mam9365@med.cornell.edu) who will review the data request with Haiti GHESKIO Site PI, Dr. Jean
320 Pape and the study's Data Safety Monitoring Board for approval.

321 Competing interests

322 VR, JWP, MLM report a grant from the Fogarty International Center, grant number R21 TW011693. The
323 remaining authors declare they have no conflicts of interest.

324 Funding

325 Funding for this study comes from the Fogarty International Center, grant number R21 TW011693. The
326 funders had no role in the study design or execution of this protocol.

327 Authors contributions

328 Conceived study: VR, JWP, MLM

329 Data curation: N/A

330 Formal analysis: N/A

331 Funding acquisition: MLM

332 Investigation: VR, ED, CG, JWP

333 Methodology: LDY, VR, ED, CG, SS, MM, SO, JWP, MLM

334 Project administration and resources: VR, ED, CG, SS, JWP

335 Software: LDY

336 Writing-original draft preparation: LDY, MLM

337 Writing-review & editing: LDY, VR, ED, SS, MM, SO, JWP, MLM

338 All authors have read, and confirm that they meet, ICMJE criteria for authorship.

339 Acknowledgements

340 We acknowledge the valuable input from the Haitian College of Cardiology, the community health
341 workers who help with data collection, and the patients at GHESKIO for entrusting us with their care.

342

343

344

345

346

347

348

349

350 References

- 351 1. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics,
352 prevention, and management of cardiovascular disease in people living with HIV: A scientific
353 statement from the American Heart Association. *Circulation*. 2019 09;140(2):e98–124.
- 354 2. Xu Y, Chen X, Wang K. Global prevalence of hypertension among people living with HIV: a systematic
355 review and meta-analysis. *J Am Soc Hypertens JASH*. 2017 Aug;11(8):530–40.
- 356 3. Armah KA, Chang C-CH, Baker JV, Ramachandran VS, Budoff MJ, Crane HM, et al. Prehypertension,
357 hypertension, and the risk of acute myocardial infarction in HIV-infected and -uninfected veterans.
358 *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2014 Jan;58(1):121–9.
- 359 4. Paisible A-L, Chang C-CH, So-Armah KA, Butt AA, Leaf DA, Budoff M, et al. HIV infection,
360 cardiovascular disease risk factor profile, and risk for acute myocardial infarction. *J Acquir Immune*
361 *Defic Syndr* 1999. 2015 Feb 1;68(2):209–16.
- 362 5. Triant VA, Lee H, Hadigan C, Grinspoon SK. Increased acute myocardial infarction rates and
363 cardiovascular risk factors among patients with human immunodeficiency virus disease. *J Clin*
364 *Endocrinol Metab*. 2007 Jul;92(7):2506–12.
- 365 6. Silverberg MJ, Leyden WA, Xu L, Horberg MA, Chao CR, Towner WJ, et al. Immunodeficiency and risk
366 of myocardial infarction among HIV-positive individuals with access to care. *JAIDS J Acquir Immune*
367 *Defic Syndr*. 2014 Feb;65(2):160–6.
- 368 7. Frank TD, Carter A, Jahagirdar D, Biehl MH, Douwes-Schultz D, Larson SL, et al. Global, regional, and
369 national incidence, prevalence, and mortality of HIV, 1980–2017, and forecasts to 2030, for 195
370 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk
371 Factors Study 2017. *Lancet HIV*. 2019 Dec 1;6(12):e831–59.
- 372 8. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global Disparities of
373 Hypertension Prevalence and Control. *Circulation*. 2016 Aug 9;134(6):441–50.
- 374 9. GBD 2017 Risk Factor Collaborators. Global, regional, and national comparative risk assessment of
375 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195
376 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study
377 2017. *The Lancet*. 2018 Nov 10;392(10159):1923–94.
- 378 10. Haitian Institute of Childhood (IHE), ICF. Mortality, Morbidity and the Utilization Survey (EMMUS-VI
379 2016-2017). Pétion-Ville, Haiti and Rockville, Maryland, USA: IHE and ICF; 2018.
- 380 11. Tymejczyk O, McNairy ML, Petion JS, Rivera VR, Dorélien A, Peck M, et al. Hypertension prevalence
381 and risk factors among residents of four slum communities: population-representative findings from
382 Port-au-Prince, Haiti. *J Hypertens*. 2019 Apr;37(4):685–95.
- 383 12. McNairy ML, Tymejczyk O, Rivera V, Seo G, Dorélien A, Peck M, et al. High Burden of Non-
384 communicable Diseases among a Young Slum Population in Haiti. *J Urban Health Bull N Y Acad Med*.
385 2019 Jun 19;

- 386 13. Batavia AS, Severe P, Lee MH, Apollon A, Zhu YS, Dupnik KM, et al. Blood pressure and mortality in a
387 prospective cohort of HIV-infected adults in Port-au-Prince, Haiti. *J Hypertens*. 2018 Jul;36(7):1533–
388 9.
- 389 14. Rapsomaniki E, Timmis A, George J, Pujades-Rodriguez M, Shah AD, Denaxas S, et al. Blood pressure
390 and incidence of twelve cardiovascular diseases: lifetime risks, healthy life-years lost, and age-
391 specific associations in 1.25 million people. *Lancet*. 2014 May 31;383(9932):1899–911.
- 392 15. Huang Y, Su L, Cai X, Mai W, Wang S, Hu Y, et al. Association of all-cause and cardiovascular
393 mortality with prehypertension: A meta-analysis. *Am Heart J*. 2014 Feb 1;167(2):160-168.e1.
- 394 16. Fuchs FD, de Mello RB, Fuchs SC. Preventing the progression of prehypertension to hypertension:
395 role of antihypertensives. *Curr Hypertens Rep*. 2015;17(1):505.
- 396 17. Nissen SE, Tuzcu EM, Libby P, Thompson PD, Ghali M, Garza D, et al. Effect of antihypertensive
397 agents on cardiovascular events in patients with coronary disease and normal blood pressure: the
398 CAMELOT study: a randomized controlled trial. *JAMA*. 2004 Nov 10;292(18):2217–25.
- 399 18. Heart Outcomes Prevention Evaluation Study Investigators, Yusuf S, Sleight P, Pogue J, Bosch J,
400 Davies R, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular
401 events in high-risk patients. *N Engl J Med*. 2000 Jan 20;342(3):145–53.
- 402 19. Xie X, Atkins E, Lv J, Bennett A, Neal B, Ninomiya T, et al. Effects of intensive blood pressure
403 lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis.
404 *Lancet Lond Engl*. 2016 Jan 30;387(10017):435–43.
- 405 20. SPRINT Research Group, Wright JT, Williamson JD, Whelton PK, Snyder JK, Sink KM, et al. A
406 Randomized Trial of Intensive versus Standard Blood-Pressure Control. *N Engl J Med*. 2015 Nov
407 26;373(22):2103–16.
- 408 21. NCD Management-Screening, Diagnosis and Treatment. HEARTS Technical Package [Internet]. WHO;
409 2018 Jun [cited 2021 Jan 7]. Available from: [https://www.who.int/publications-detail-
410 redirect/hearts-technical-package](https://www.who.int/publications-detail-redirect/hearts-technical-package)
- 411 22. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Dennison Himmelfarb C, et al. 2017
412 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,
413 Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A
414 Report of the American College of Cardiology/American Heart Association Task Force on Clinical
415 Practice Guidelines. *Circulation*. 2018 Oct 23;138(17):e426–83.
- 416 23. Krikke M, Hoogeveen RC, Hoepelman AIM, Visseren FLJ, Arends JE. Cardiovascular risk prediction in
417 HIV-infected patients: comparing the Framingham, atherosclerotic cardiovascular disease risk score
418 (ASCVD), Systematic Coronary Risk Evaluation for the Netherlands (SCORE-NL) and Data Collection
419 on Adverse Events of Anti-HIV Drugs (D:A:D) risk prediction models. *HIV Med*. 2016 Apr;17(4):289–
420 97.
- 421 24. Centers for Disease Control and Prevention (CDC). National Center for Health Statistics (NCHS).
422 National Health and Nutrition Examination Survey Data [Internet]. Hyattsville, MD: U.S. Department

- 423 of Health and Human Services, Centers for Disease Control and Prevention,; 2011 2014. Available
424 from: [<https://wwwn.cdc.gov/nchs/nhanes/continuousnhanes/default.aspx?BeginYear=2011>]
- 425 25. Glesby MJ, Aberg JA, Kendall MA, Fichtenbaum CJ, Hafner R, Hall S, et al. Pharmacokinetic
426 interactions between indinavir plus ritonavir and calcium channel blockers. *Clin Pharmacol Ther.*
427 2005 Aug;78(2):143–53.
- 428 26. Inaugural Clinical Conference of GHESKIO Centers on Cardiovascular Disease [Internet]. Port-au-
429 Prince, Haiti; Available from:
430 [https://globalhealth.weill.cornell.edu/sites/default/files/cvd_haiti_meeting_summary_with_htn_pri-](https://globalhealth.weill.cornell.edu/sites/default/files/cvd_haiti_meeting_summary_with_htn_primary_care_guidelnes_version_1.0.pdf)
431 [mary_care_guidelnes_version_1.0.pdf](https://globalhealth.weill.cornell.edu/sites/default/files/cvd_haiti_meeting_summary_with_htn_primary_care_guidelnes_version_1.0.pdf)
- 432 27. DAIDS Adverse Event Grading Tables | DAIDS Regulatory Support Center (RSC) [Internet]. [cited
433 2021 Feb 8]. Available from: [https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-](https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables)
434 [grading-tables](https://rsc.niaid.nih.gov/clinical-research-sites/daids-adverse-event-grading-tables)
- 435 28. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, et al. Self-reported adherence
436 to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence
437 Instruments. *AIDS Care.* 2000 Jun 1;12(3):255–66.
- 438 29. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High
439 Blood Pressure Therapy Scale. *Prog Cardiovasc Nurs.* 2000;15(3):90–6.
- 440 30. Diggle P, Heagerty P, Liang K-Y, Zeger S. *Analysis of Longitudinal Data.* Second Edition. Oxford, New
441 York: Oxford University Press; 2002. 396 p. (Oxford Statistical Science Series).
- 442 31. Triant VA, Perez J, Regan S, Massaro JM, Meigs JB, Grinspoon SK, et al. Cardiovascular Risk
443 Prediction Functions Underestimate Risk in HIV Infection. *Circulation.* 2018 May 22;137(21):2203–
444 14.
- 445

Randomized
participants
(n = 250)

Prehypertension Treatment Arm
(n = 125)

Standard of Care Arm
(n = 125)

Months

0

1

3

6

9

12

Clinic
Study Visit

Clinic
Study Visit

Clinic
Study Visit

Clinic
Study Visit

Clinic
Study Visit

Enrollment